Characterizing microglial gene expression in a model of secondary progressive multiple sclerosis

Ilia D Vainchtein1, Astrid M Alsema1, Marissa L Dubbelaar1

  • 1Department of Biomedical Sciences of Cells & Systems, Section Molecular Neurobiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Glia
|November 15, 2022
PubMed

Insights

Microglia in experimental autoimmune encephalomyelitis (EAE), a multiple sclerosis model, change phenotypes throughout disease stages. Understanding chronic EAE microglia is key for developing therapies for progressive multiple sclerosis.

Area of Science:

  • Neuroimmunology
  • Cellular and Molecular Neuroscience

Background:

  • Multiple sclerosis (MS) is a leading cause of neurological disability in young adults.
  • The role of microglia, the central nervous system's immune cells, is unclear in MS, particularly in its progressive phases.
  • Chronic-relapsing experimental autoimmune encephalomyelitis (crEAE) in mice serves as a model for MS.

Purpose of the Study:

  • To investigate the dynamic changes in microglia phenotypes during different phases of crEAE.
  • To characterize microglia's role in acute, remission, and chronic stages of this MS model.

Main Methods:

  • Morphometric analysis of microglia.
  • RNA sequencing to analyze gene expression profiles of microglia.
  • Utilizing the crEAE mouse model.

Main Results:

  • During the acute phase, microglia exhibited a pro-inflammatory phenotype.
  • In the remission phase, microglia showed decreased immune gene expression and increased genes for lipid metabolism and tissue repair.
  • Chronic phase microglia displayed a mixed phenotype, with partial restoration of inflammatory genes and increased proliferation markers.

Conclusions:

  • Microglia adopt distinct phenotypes across different stages of crEAE.
  • The chronic stage is characterized by a complex, mixed microglia phenotype.
  • Insights into chronic-stage microglia are crucial for understanding secondary progressive MS and developing targeted therapies.

Related Concept Videos